GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Cognetivity Neurosciences Ltd (XCNQ:CGN) » Definitions » Debt-to-Asset

Cognetivity Neurosciences (XCNQ:CGN) Debt-to-Asset : 5.62 (As of Oct. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Cognetivity Neurosciences Debt-to-Asset?

Cognetivity Neurosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was C$1.37 Mil. Cognetivity Neurosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2023 was C$1.37 Mil. Cognetivity Neurosciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Oct. 2023 was C$0.49 Mil. Cognetivity Neurosciences's debt to asset for the quarter that ended in Oct. 2023 was 5.62.


Cognetivity Neurosciences Debt-to-Asset Historical Data

The historical data trend for Cognetivity Neurosciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cognetivity Neurosciences Debt-to-Asset Chart

Cognetivity Neurosciences Annual Data
Trend Jan17 Jan18 Jan19 Jan20 Jan21 Jan22 Jan23
Debt-to-Asset
Get a 7-Day Free Trial - 0.41 0.17 0.65 0.46

Cognetivity Neurosciences Quarterly Data
Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.46 1.03 2.48 5.62

Competitive Comparison of Cognetivity Neurosciences's Debt-to-Asset

For the Health Information Services subindustry, Cognetivity Neurosciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cognetivity Neurosciences's Debt-to-Asset Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cognetivity Neurosciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Cognetivity Neurosciences's Debt-to-Asset falls into.



Cognetivity Neurosciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Cognetivity Neurosciences's Debt-to-Asset for the fiscal year that ended in Jan. 2023 is calculated as

Cognetivity Neurosciences's Debt-to-Asset for the quarter that ended in Oct. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cognetivity Neurosciences  (XCNQ:CGN) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Cognetivity Neurosciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Cognetivity Neurosciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Cognetivity Neurosciences (XCNQ:CGN) Business Description

Traded in Other Exchanges
Address
800 West Pender Street, Suite 1430, Vancouver, BC, CAN, V6C 2V6
Cognetivity Neurosciences Ltd is a technology company developing a cognitive testing platform, the Integrated Cognitive Assessment (ICA), for use in medical, commercial, and consumer environments for potentially allowing early diagnosis of dementia. The Company is considered operating in one segment for development of the ICA platform. Its geographical areas include Canada, United Kingdom and Dubai.
Executives
Ravinder Kang Director

Cognetivity Neurosciences (XCNQ:CGN) Headlines

No Headlines